BioSpace News Archive

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announced that 4D management will present at three upcoming investor conferences:

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Douglas J. Swirsky as Chief Financial Officer and Treasurer effective February 1, 2021.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will participate in two upcoming investor conferences in March: H.C. Wainwright Global Life Sciences Conference, March 10, 2021. Company presentation will be available for on-demand viewing at 7:00 a.m. ET on Tuesday, March 9, 2021.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions, today announced its participation in the following investor conferences in March: H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 am (Eastern Time)

Expects preliminary Phase 1/2 safety and biomarker and preliminary clinical data for TSHA-101 in GM2 gangliosidosis from the Queen’s University study in second half of 2021 and by year-end 2021, respectively Plans to initiate Phase 1/2 clinical trial for TSHA-118 in CLN1 disease in the second half of 2021 and Phase 1/2 clinical trials for TSHA-102 in Rett syndrome and TSHA-104 in SURF1-associated Leigh syndrome by year-end

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at two upcoming virtual investor conferences. H.C. Wainwright Global Life Sciences Conference March 9-10, 2021

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the H.C. Wainwright Annual Global Life Sciences Conference, taking place March 9-10, 2021. .

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two investor conferences in March. Jack Bailey, G1’s Chief Executive Officer, will provide a presentation during the HC Wainwright Global Life Sciences Conference; this presentation will be available starting on March 9, 2021 at 7:00 AM ET.

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at the following upcoming virtual conferences. Event H.C. Wainwright Global Life Sciences Conference Date March 9-10, 2021

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience announced today that Kineta will be presenting at multiple virtual investor events in March 2021.